ClinicalTrials.gg
CompletedNCT05938920Updated Dec 11, 2025Results posted

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)

A Phase 2 interventional study of INS018_055 and Placebo in Idiopathic Pulmonary Fibrosis (IPF), sponsored by InSilico Medicine Hong Kong Limited. Completed at 22 sites in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by InSilico Medicine Hong Kong Limited · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China — 25 open to participants now, 29 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · China.

Enrollment
35th of 60
71 · median 83
Started
2023
with 7 others
Phase 2
21 of 67
7 open now
Registered
29th of 67
by date

Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, this one is the 35th largest by enrollment of the 60 interventional ones that give a count, is one of 8 that started in 2023, is one of 21 in phase 2, and was the 29th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

25 of the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF).

The primary objective is to evaluate the safety and tolerability of INS018_055 orally administered for up to 12 weeks in adult subjects with IPF compared to placebo.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis (IPF)

Keywords

  • Pulmonary Fibrosis
  • Idiopathic Pulmonary Fibrosis
  • Fibrosis
  • Pathologic Processes
  • Lung Diseases, Interstitial
  • Lung Diseases
  • Respiratory Tract Diseases
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients aged ≥40 years based on the date of the written form
  2. Diagnosis of IPF as defined by American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guidelines
  3. In a stable condition and suitable for study participation based on the results of medical history, physical examination, vital signs, 12-lead , and laboratory evaluation
  4. Subjects with background pirfenidone or nintedanib may be enrolled if their regimen of antifibrotic therapy has been stable for > 8 weeks prior to Visit 1
  5. Meeting all of the following criteria during the screening period:

    1. FVC ≥40% predicted of normal
    2. DLCO corrected for ≥25% and \<80% predicted of normal.
    3. /FVC (FEV1/FVC) ratio >0.7 based on pre-bronchodilator value

Exclusion criteria

Exclusion Criteria:

  1. Acute IPF exacerbation within 4 months prior to Visit 1 and/or during the screening period, as determined by the investigator
  2. Patients who are unwilling to refrain from smoking within 3 months prior to screening and until the end of the study
  3. Female patients who are pregnant or nursing
  4. Abnormal findings

Other protocol inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    INS018_055 30 mg QD

    Group 1: INS018\_055 once daily up to 12 weeks, low dose

    Drug: INS018_055

  • Experimental
    INS018_055 30 mg BID

    Group 2: INS018\_055 twice daily up to 12 weeks, low dose

    Drug: INS018_055

  • Experimental
    INS018_055 60 mg QD

    Group 3: INS018\_055 once daily up to 12 weeks, high dose

    Drug: INS018_055

  • Placebo comparator
    Placebo

    Group 4: Placebo once or twice daily up to 12 weeks

    Drug: Placebo

Interventions

  • Pharmaceutical formulation: Capsules Mode of Administration: Oral

  • DrugPlacebo

    Pharmaceutical formulation: Capsules Mode of Administration: Oral

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Had at Least 1 Treatment-emergent Adverse Event (TEAE)

    TEAEs were either events with start date on or after the start of the Treatment Period and up to 17 days after EOT (end of treatment), or events with start date prior to the start of the Treatment Period whose severity worsened on or after the start of the Treatment Period and up to 17 days after EOT. CTCAE=Common Terminology Criteria for Adverse Events

    Time frame: From first dose of study drug until end of study (EOS) visit i.e. up to 13 weeks (+10 days)

Secondary outcomes

  1. Relative Change From Baseline in Forced Vital Capacity (FVC)

    Decline (change) in FVC is presented from Week 0 to Week 12. FVC was assessed using standardized spirometry equipment.

    Time frame: Week 0/Visit 2 up to Week 12

  2. Absolute Change From Baseline in FVC in L

    Decline (change) in FVC is presented from Week 0 to Week 12. FVC was assessed using standardized spirometry equipment.

    Time frame: Week 0/Visit 2 up to Week 12

  3. Absolute Change in FVC % Predicted

    Absolute change in FVC % predicted from Week 0 to Week 12 is presented. FVC was assessed using standardized spirometry equipment

    Time frame: Week 0/Visit 2 up to Week 12

  4. Relative Change in FVC % Predicted

    Relative change in FVC % predicted from Week 0 to Week 12 is presented. FVC was assessed using standardized spirometry equipment

    Time frame: Week 0/Visit 2 up to Week 12

07

Results

Posted Dec 2, 2025

Participant flow

Participant flow — Overall Study
MilestoneINS018_055 30 mg QDINS018_055 30 mg BIDINS018_055 60 mg QDPlacebo
Started18181817
Completed16141316
Not completed2451
Withdrew: Adverse event1321
Withdrew: Death0100
Withdrew: Lost to follow-up0010
Withdrew: Participant asked to withdraw from the trial1000
Withdrew: Participant withdrew from treatment and refused to do visit 7 follow up visit0010
Withdrew: Participant refused to come in0010

Outcome measures

PrimaryPercentage of Participants Who Had at Least 1 Treatment-emergent Adverse Event (TEAE)

TEAEs were either events with start date on or after the start of the Treatment Period and up to 17 days after EOT (end of treatment), or events with start date prior to the start of the Treatment Period whose severity worsened on or after the start of the Treatment Period and up to 17 days after EOT. CTCAE=Common Terminology Criteria for Adverse Events

Time frame:
From first dose of study drug until end of study (EOS) visit i.e. up to 13 weeks (+10 days)
Reported as:
Count of participants · Participants
Percentage of Participants Who Had at Least 1 Treatment-emergent Adverse Event (TEAE)
ParticipantsINS018_055 30 mg QDINS018_055 30 mg BIDINS018_055 60 mg QDPlacebo
Any TEAE13151512
TEAE with CTCAE grade ≥33784
TEAE Leading to discontinuation of treatment1542
TEAE Leading to death0100
SecondaryRelative Change From Baseline in Forced Vital Capacity (FVC)

Decline (change) in FVC is presented from Week 0 to Week 12. FVC was assessed using standardized spirometry equipment.

Time frame:
Week 0/Visit 2 up to Week 12
Reported as:
Mean · percentage change in FVC
Relative Change From Baseline in Forced Vital Capacity (FVC)
percentage change in FVCINS018_055 30 mg QDINS018_055 30 mg BIDINS018_055 60 mg QDPlacebo
Relative Change From Baseline in Forced Vital Capacity (FVC)-0.7923 ± 3.905080.6821 ± 6.095853.2253 ± 5.27457-0.7126 ± 8.17452
Statistical analysis
  • INS018_055 30 mg QD · Least squares mean: -0.6098 · 95% CI -4.1026 to 2.8831
  • INS018_055 30 mg BID · Least squares mean: 0.6721 · 95% CI -3.0738 to 4.4179
  • INS018_055 60 mg QD · Least squares mean: 2.8232 · 95% CI -1.6970 to 7.3433
  • Placebo · Least squares mean: -0.2933 · 95% CI -4.5273 to 3.9408
SecondaryAbsolute Change From Baseline in FVC in L

Decline (change) in FVC is presented from Week 0 to Week 12. FVC was assessed using standardized spirometry equipment.

Time frame:
Week 0/Visit 2 up to Week 12
Reported as:
Mean · L
Absolute Change From Baseline in FVC in L
LINS018_055 30 mg QDINS018_055 30 mg BIDINS018_055 60 mg QDPlacebo
Absolute Change From Baseline in FVC in L-0.0270 ± 0.113680.0197 ± 0.141770.0984 ± 0.14113-0.0203 ± 0.18300
Statistical analysis
  • INS018_055 30 mg QD · Least squares mean: -0.0242 · 95% CI -0.1050 to 0.0566
  • INS018_055 30 mg BID · Least squares mean: 0.0194 · 95% CI -0.0687 to 0.1074
  • INS018_055 60 mg QD · Least squares mean: 0.0892 · 95% CI -0.0087 to 0.1872
  • Placebo · Least squares mean: -0.0082 · 95% CI -0.0981 to 0.0817
SecondaryAbsolute Change in FVC % Predicted

Absolute change in FVC % predicted from Week 0 to Week 12 is presented. FVC was assessed using standardized spirometry equipment

Time frame:
Week 0/Visit 2 up to Week 12
Reported as:
Mean · Percent predicted
Absolute Change in FVC % Predicted
Percent predictedINS018_055 30 mg QDINS018_055 30 mg BIDINS018_055 60 mg QDPlacebo
Absolute Change in FVC % Predicted-0.6729 ± 2.925540.6455 ± 3.734823.0461 ± 4.38853-0.5675 ± 5.44712
Statistical analysis
  • INS018_055 30 mg QD · Least squares mean: -0.6043 · 95% CI -2.9549 to 1.7462
  • INS018_055 30 mg BID · Least squares mean: 0.6510 · 95% CI -1.9603 to 3.2624
  • INS018_055 60 mg QD · Least squares mean: 2.4975 · 95% CI -0.3187 to 5.3136
  • Placebo · Least squares mean: -0.0209 · 95% CI -2.8142 to 2.7724
SecondaryRelative Change in FVC % Predicted

Relative change in FVC % predicted from Week 0 to Week 12 is presented. FVC was assessed using standardized spirometry equipment

Time frame:
Week 0/Visit 2 up to Week 12
Reported as:
Mean · Percent predicted
Relative Change in FVC % Predicted
Percent predictedINS018_055 30 mg QDINS018_055 30 mg BIDINS018_055 60 mg QDPlacebo
Relative Change in FVC % Predicted-0.6724 ± 4.055370.4434 ± 5.968953.2194 ± 5.28129-0.8414 ± 8.31651
Statistical analysis
  • INS018_055 30 mg QD · Least squares mean: -0.5762 · 95% CI -4.0035 to 2.8511
  • INS018_055 30 mg BID · Least squares mean: 0.5884 · 95% CI -3.1449 to 4.3216
  • INS018_055 60 mg QD · Least squares mean: 2.6554 · 95% CI -1.8486 to 7.1593
  • Placebo · Least squares mean: -0.0625 · 95% CI -4.3227 to 4.1977

Adverse events

Collected over Adverse events (AEs) were collected from the signing of the informed consent form (ICF) until end of study (EOS) visit i.e. up to 13 weeks (+10 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
INS018_055 30 mg QD0/18 (0%)2/18 (11.1%)13/18 (72.2%)
INS018_055 30 mg BID1/18 (5.6%)4/18 (22.2%)15/18 (83.3%)
INS018_055 60 mg QD0/18 (0%)7/18 (38.9%)15/18 (83.3%)
Placebo0/17 (0%)3/17 (17.6%)12/17 (70.6%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventINS018_055 30 mg QDINS018_055 30 mg BIDINS018_055 60 mg QDPlacebo
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders0/180/183/180/17
PneumoniaInfections and infestations0/180/182/180/17
DyspnoeaRespiratory, thoracic and mediastinal disorders0/180/181/181/17
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/180/180/181/17
Upper respiratory tract infectionInfections and infestations0/180/180/181/17
Chronic gastritisGastrointestinal disorders0/180/180/181/17
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders0/180/181/180/17
Respiratory failureRespiratory, thoracic and mediastinal disorders0/180/181/180/17
Liver injuryHepatobiliary disorders0/181/181/180/17
Drug-induced liver injuryHepatobiliary disorders0/181/180/180/17
Most frequent other events
Showing 10 of 118
Most frequent other events
EventINS018_055 30 mg QDINS018_055 30 mg BIDINS018_055 60 mg QDPlacebo
Alanine aminotransferase increasedInvestigations1/181/186/181/17
HypokalemiaMetabolism and nutrition disorders3/185/184/182/17
DiarrhoeaGastrointestinal disorders2/183/185/180/17
Blood bilirubin increasedInvestigations0/181/184/182/17
Upper respiratory tract infectionInfections and infestations1/184/181/181/17
Hepatic function abnormalHepatobiliary disorders2/184/183/182/17
Respiratory tract infectionInfections and infestations0/181/182/183/17
NasopharyngitisInfections and infestations0/180/180/182/17
Aspartate aminotransferase increasedInvestigations1/181/182/180/17
Blood lactate dehydrogenase increasedInvestigations0/180/182/180/17

Baseline characteristics

Intent-to-treat (ITT) Population

Age, Continuous
Age, Continuous(years)INS018_055 30 mg QDINS018_055 30 mg BIDINS018_055 60 mg QDPlaceboTotal
Mean65.8 ± 6.9967.2 ± 7.7765.7 ± 6.8268.3 ± 5.2866.7 ± 6.73
Age, Customized
Age, Customized(Participants)INS018_055 30 mg QDINS018_055 30 mg BIDINS018_055 60 mg QDPlaceboTotal
≤ 65 years977427
> 65 to ≤ 75 years79101339
>75 years22105
Sex: Female, Male
Sex: Female, Male(Participants)INS018_055 30 mg QDINS018_055 30 mg BIDINS018_055 60 mg QDPlaceboTotal
Female03227
Male1815161564
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)INS018_055 30 mg QDINS018_055 30 mg BIDINS018_055 60 mg QDPlaceboTotal
Hispanic or Latino00000
Not Hispanic or Latino1818181771
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)INS018_055 30 mg QDINS018_055 30 mg BIDINS018_055 60 mg QDPlaceboTotal
American Indian or Alaska Native00000
Asian1818181771
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
Height at Baseline
Height at Baseline(centimeters (cm))INS018_055 30 mg QDINS018_055 30 mg BIDINS018_055 60 mg QDPlaceboTotal
Mean167.77 ± 5.549165.78 ± 7.869166.29 ± 6.470164.50 ± 7.874166.11 ± 6.944
Weight at Baseline
Weight at Baseline(kilograms (kg))INS018_055 30 mg QDINS018_055 30 mg BIDINS018_055 60 mg QDPlaceboTotal
Mean72.27 ± 7.39567.36 ± 12.14173.32 ± 13.54767.69 ± 12.11770.20 ± 11.593
Body Mass Index at Baseline
Body Mass Index at Baseline(kg/m2)INS018_055 30 mg QDINS018_055 30 mg BIDINS018_055 60 mg QDPlaceboTotal
Mean25.66 ± 2.08024.41 ± 3.39926.41 ± 4.12824.96 ± 3.73325.36 ± 3.429

5 further baseline measures are reported on the registry.

08

Study locations

22 sites
  • Anhui Chest Hospital
    Hefei, Anhui 230031, China
  • The Second Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230601, China
  • Peking University Shougang Hospital
    Beijing, Beijing Municipality 100041, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing Municipality 100050, China
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality 100730, China
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510080, China
  • Nanfang Hospital of Southern Medical University
    Guangzhou, Guangdong 510515, China
  • Hainan General Hospital
    Haikou, Hainan 570311, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
  • Xiangya Hospital of Central South University
    Changsha, Hunan 410008, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu 210008, China
  • Jiangxi Provincial People's Hospital
    Nanchang, Jiangxi 330006, China
  • The Shengjing Hospital of China medical university
    Shenyang, Liaoning 110004, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250013, China
  • Shanghai Chest Hospital
    Shanghai, Shanghai Municipality 200030, China
  • Zhongshan hospital Fudan University
    Shanghai, Shanghai Municipality 200032, China
  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai Municipality 201800, China
  • Shanxi Bethune Hospital
    Taiyuan, Shanxi 030032, China
  • The West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
  • General Hospital of Tianjin Medical University
    Tianjin, Tianjin Municipality 300052, China
  • The First Affiliated Hospital - Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310006, China
09

References and documents

Publications

  • Xu Z, Ren F, Wang P, Cao J, Tan C, Ma D, Zhao L, Dai J, Ding Y, Fang H, Li H, Liu H, Luo F, Meng Y, Pan P, Xiang P, Xiao Z, Rao S, Satler C, Liu S, Lv Y, Zhao H, Chen S, Cui H, Korzinkin M, Gennert D, Zhavoronkov A. A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. Nat Med. 2025 Aug;31(8):2602-2610. doi: 10.1038/s41591-025-03743-2. Epub 2025 Jun 3. PubMed 40461817 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Aug 2024, 13 months.

Results were first posted in Dec 2025, 1 year 3 months after primary completion.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 13 months is below that.

Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2023
First posted
Jul 11, 2023
StartActual
Jun 19, 2023
Primary completionActual
Aug 8, 2024
CompletionActual
Aug 8, 2024
Results first posted
Dec 2, 2025
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05938920
Lead sponsor
InSilico Medicine Hong Kong Limited
Responsible party
Sponsor
First posted
Jul 11, 2023
Start date
Jun 19, 2023
Primary completion
Aug 8, 2024
Completion
Aug 8, 2024
Results posted
Dec 2, 2025
Last update
Dec 11, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rentosertib

Start the discussion